Loading…
Medico Intercontinental (BSE 539938)₹25.75+1.06%Trading & Distributors
In the Jun 2026 quarter (consolidated), Medico Intercontinental reported sales of ₹20.69 Cr, down 3.0% from Jun 2025, and net profit of −₹4.04 Cr. For the year to Mar 2026, sales were ₹83.99 Cr and net profit −₹10.96 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.10 | 14.23 | 15.69 | 19.25 | 36.41 | 18.41 | 21.13 | 21.33 | 20.37 | 19.82 | 22.48 | 20.69 |
| Expenses | 15.86 | 12.80 | 14.19 | 17.69 | 33.83 | 16.58 | 19.28 | 20.72 | 21.34 | 18.33 | 20.93 | 21.46 |
| Operating Profit | 1.30 | 1.48 | 1.54 | 1.63 | 2.70 | 1.90 | 1.93 | 0.67 | −0.87 | 1.58 | 1.60 | −0.68 |
| OPM % | 7.6% | 10.4% | 9.9% | 8.5% | 7.4% | 10.3% | 9.1% | 3.2% | −4.3% | 8.0% | 7.1% | −3.3% |
| Other Income | 0.09 | 0.10 | 0.15 | 0.12 | 0.11 | 0.14 | 0.12 | 0.30 | 0.56 | 0.35 | 0.12 | 0.14 |
| Interest | 0.10 | 0.14 | 0.17 | 0.19 | 0.29 | 0.25 | 0.31 | 2.37 | 2.07 | 1.91 | 1.86 | 1.92 |
| Depreciation | 0.06 | 0.06 | 0.07 | 0.07 | 0.19 | 0.22 | 0.27 | 0.61 | 1.94 | 1.42 | 1.42 | 1.20 |
| Profit before tax | 1.24 | 1.39 | 1.46 | 1.50 | 2.34 | 1.58 | 1.48 | −2.02 | −4.35 | −1.41 | −1.57 | −3.69 |
| Tax % | 29.3% | 26.1% | 28.3% | 27.6% | 29.6% | 27.4% | 22.4% | 23.9% | 4.6% | 20.0% | 51.3% | 10.3% |
| Net Profit | 0.86 | 1.01 | 1.03 | 1.07 | 1.62 | 1.16 | 1.16 | −2.48 | −4.50 | −1.65 | −2.32 | −4.04 |
| EPS (Rs) | 0.86 | 1.01 | 1.03 | 1.07 | 1.62 | 1.16 | 1.16 | −0.67 | −1.64 | −0.21 | −0.64 | −1.44 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 9.99 | 81.99 | 69.98 | 73.96 | 75.92 | 70.94 | 95.88 | 83.99 | 83.36 |
| Expenses | 0.00 | 9.02 | 78.20 | 65.24 | 69.17 | 71.21 | 66.19 | 88.27 | 81.20 | 82.06 |
| Operating Profit | 0.00 | 0.99 | 3.99 | 4.99 | 4.99 | 4.99 | 5.98 | 7.98 | 2.99 | 1.63 |
| OPM % | — | 7.0% | 5.0% | 7.0% | 7.0% | 7.0% | 8.0% | 9.0% | 3.5% | 2.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 1.01 | 1.17 |
| Interest | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 0.00 | 1.01 | 8.02 | 7.76 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 4.98 | 5.98 |
| Profit before tax | 0.00 | 1.01 | 3.01 | 4.01 | 4.01 | 5.01 | 5.02 | 7.02 | −9.04 | −11.02 |
| Tax % | 40.0% | 27.0% | 26.0% | 27.0% | 27.0% | 27.0% | 27.0% | 28.0% | 19.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.99 | 1.99 | 2.99 | 2.99 | 3.99 | 3.99 | 4.98 | −10.96 | −12.51 |
| EPS (Rs) | 0.08 | 2.27 | 7.24 | 7.91 | 9.50 | 3.60 | 3.93 | 5.04 | −3.19 | −3.93 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.00 | 3.01 | 3.00 | 3.00 | 10.02 | 10.02 | 10.03 | 10.03 |
| Reserves | 0.00 | 1.01 | 3.01 | 6.02 | 9.03 | 31.09 | 35.09 | 39.13 | 37.11 |
| Borrowings | 0.00 | 0.00 | 14.03 | 9.02 | 9.01 | 5.01 | 5.00 | 17.04 | 67.05 |
| Other Liabilities | 1.01 | 5.02 | 16.08 | 12.06 | 11.05 | 13.06 | 6.04 | 10.05 | 3.02 |
| Total Liabilities | 4.02 | 9.03 | 36.13 | 31.10 | 32.09 | 59.18 | 56.15 | 76.25 | 117 |
| Fixed Assets | 0.00 | 0.00 | 1.99 | 1.99 | 1.99 | 2.99 | 3.99 | 8.98 | 50.97 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 |
| Other Assets | 4.02 | 9.03 | 34.14 | 28.11 | 30.10 | 56.19 | 53.16 | 67.27 | 64.23 |
| Inventories | 0.00 | 0.62 | 8.67 | 9.10 | 7.87 | 8.87 | 10.42 | 9.23 | 14.90 |
| Trade receivables | 1.34 | 6.46 | 22.78 | 17.99 | 17.15 | 32.84 | 23.20 | 32.84 | 27.44 |
| Cash & equivalents | 0.17 | 1.19 | 0.79 | 0.52 | 1.86 | 6.78 | 3.36 | 2.70 | 5.97 |
| Total Assets | 4.02 | 9.03 | 36.13 | 31.10 | 32.09 | 59.18 | 56.15 | 76.25 | 117 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 1.01 | −14.04 | 6.02 | 4.01 | −10.03 | 6.02 | −7.03 | 17.04 |
| Cash from investing activity | 0.00 | 0.00 | −1.01 | −1.01 | −5.01 | −9.01 | −2.01 | 2.01 |
| Cash from financing activity | 0.00 | 13.05 | −5.02 | −1.01 | 20.09 | 0.00 | 9.03 | −16.06 |
| Net cash flow | 1.01 | 0.00 | 0.00 | 1.01 | 5.01 | −3.01 | −1.01 | 4.01 |
| Capex | 0.00 | 0.00 | 0.82 | 0.22 | 0.43 | 1.24 | 2.01 | 4.65 |
| Free cash flow | 1.01 | −14.05 | 5.02 | 4.02 | −11.04 | 4.02 | −9.04 | 12.05 |
| CFO / OP % | 171.1% | −199.9% | 138.1% | 100.1% | −166.9% | 118.1% | −63.0% | 635.1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 236 | 100 | 93 | 83 | 156 | 118 | 124 | 118 |
| Inventory days | 26 | 46 | 58 | 47 | 52 | 69 | 45 | 87 |
| Days payable | 202 | 75 | 68 | 51 | 68 | 31 | 38 | 83 |
| Cash conversion cycle | 61 | 73 | 84 | 80 | 142 | 157 | 133 | 123 |
| Working capital days | 79 | 75 | 69 | 67 | 133 | 135 | 157 | 77 |
| ROCE % | 27.9% | 36.0% | 25.0% | 25.0% | 16.9% | 11.9% | 13.9% | −1.0% |
For the Jun 2026 quarter, Medico Intercontinental reported sales of ₹20.69 Cr, down 3.0% year on year and net profit of −₹4.04 Cr. The operating margin was −3.3%.
Medico Intercontinental's sales for the year to Mar 2026 were ₹83.99 Cr; over the last twelve months they were ₹83.36 Cr.
Net profit for the year to Mar 2026 was −₹10.96 Cr, and −₹12.51 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−3.93.
Medico Intercontinental reported borrowings of ₹67.05 Cr at Mar 2026, against cash and equivalents of ₹5.97 Cr.
Cash from operations was ₹17.04 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹12.05 Cr.